Alphamab Oncology (HK:9966) has released an update.
Alphamab Oncology has announced a significant collaboration with ArriVent BioPharma to develop and commercialize novel antibody drug conjugates (ADCs) using Alphamab’s proprietary platforms. Alphamab retains rights within the Greater China Region while ArriVent handles the rest, with Alphamab eligible for up to $615.5 million in milestone payments and sales royalties. The partnership aims to leverage both companies’ expertise to address unmet medical needs in oncology.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
